388 related articles for article (PubMed ID: 29455579)
41. Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence.
McEvoy JP
J Clin Psychiatry; 2020 Sep; 81(6):. PubMed ID: 32991793
[TBL] [Abstract][Full Text] [Related]
42. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 29024264
[TBL] [Abstract][Full Text] [Related]
43. Tardive Dyskinesia: New Treatments Available.
Limandri BJ
J Psychosoc Nurs Ment Health Serv; 2019 May; 57(5):11-14. PubMed ID: 31042295
[TBL] [Abstract][Full Text] [Related]
44. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
Dean M; Sung VW
Drug Des Devel Ther; 2018; 12():313-319. PubMed ID: 29497277
[TBL] [Abstract][Full Text] [Related]
45. Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects.
Stahl SM
CNS Spectr; 2018 Feb; 23(1):1-6. PubMed ID: 29249207
[TBL] [Abstract][Full Text] [Related]
46. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
Factor SA; Remington G; Comella CL; Correll CU; Burke J; Jimenez R; Liang GS; O'Brien CF
J Clin Psychiatry; 2017; 78(9):1344-1350. PubMed ID: 29141124
[TBL] [Abstract][Full Text] [Related]
47. Dopamine depleters in the treatment of hyperkinetic movement disorders.
Jankovic J
Expert Opin Pharmacother; 2016 Dec; 17(18):2461-2470. PubMed ID: 27819145
[TBL] [Abstract][Full Text] [Related]
48. Valbenazine: First Global Approval.
Kim ES
Drugs; 2017 Jul; 77(10):1123-1129. PubMed ID: 28578484
[TBL] [Abstract][Full Text] [Related]
49. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.
Grigoriadis DE; Smith E; Hoare SRJ; Madan A; Bozigian H
J Pharmacol Exp Ther; 2017 Jun; 361(3):454-461. PubMed ID: 28404690
[TBL] [Abstract][Full Text] [Related]
50. Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient's Perspective.
Josiassen RC; Filmyer DM; Gillean J; Shah SS; Dietterich TE; Shaughnessy RA
Am J Case Rep; 2017 Nov; 18():1185-1189. PubMed ID: 29114100
[TBL] [Abstract][Full Text] [Related]
51. Deutetrabenazine for the treatment of Huntington's chorea.
Bashir H; Jankovic J
Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
[TBL] [Abstract][Full Text] [Related]
52. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia.
Meyer JM
CNS Spectr; 2016 Dec; 21(S1):13-24. PubMed ID: 28044943
[TBL] [Abstract][Full Text] [Related]
53. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
Paton DM
Drugs Today (Barc); 2017 Feb; 53(2):89-102. PubMed ID: 28387387
[TBL] [Abstract][Full Text] [Related]
54. Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine.
Skor H; Smith EB; Loewen G; O'Brien CF; Grigoriadis DE; Bozigian H
Drugs R D; 2017 Sep; 17(3):449-459. PubMed ID: 28776237
[TBL] [Abstract][Full Text] [Related]
55. Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia.
Aggarwal S; Serbin M; Yonan C
J Comp Eff Res; 2019 Oct; 8(13):1077-1088. PubMed ID: 31464152
[No Abstract] [Full Text] [Related]
56. Valbenazine Treatment of Tardive Dyskinesia and of Positive Symptoms.
Lindenmayer JP; Burke E; Tsuboyama G; Chahal Y; Grewal HK
J Clin Psychopharmacol; 2022 Jan-Feb 01; 42(1):109-111. PubMed ID: 34668876
[No Abstract] [Full Text] [Related]
57. VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine).
Harriott ND; Williams JP; Smith EB; Bozigian HP; Grigoriadis DE
Prog Med Chem; 2018; 57(1):87-111. PubMed ID: 29680151
[TBL] [Abstract][Full Text] [Related]
58. Case Report: Valbenazine as a Treatment for Tardive Dyskinesia and Unexpected Antipsychotic Effects.
Khurram SK; Ames M; Muniz J
J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):220-221. PubMed ID: 33587391
[No Abstract] [Full Text] [Related]
59. Treatment Recommendations for Tardive Dyskinesia.
Ricciardi L; Pringsheim T; Barnes TRE; Martino D; Gardner D; Remington G; Addington D; Morgante F; Poole N; Carson A; Edwards M
Can J Psychiatry; 2019 Jun; 64(6):388-399. PubMed ID: 30791698
[TBL] [Abstract][Full Text] [Related]
60. Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2017 Jul; 71(7):. PubMed ID: 28497864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
